Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of <i>Helicobacter pylori</i> infection

Adachi, Kyoichi; Fujishiro, Hirofumi; Mihara, Takafumi; Komazawa, Yoshinori; Kinoshita, Yoshikazu

doi:10.1046/j.1440-1746.2003.02922.x

Cited by 29 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However the results could not be explained by the hypothesis that rebamipide has the function of eliminating H. pylori, even though we have found the H. pylori infection rate in the rebamipide group to be lower than in the sucralfate group. What we can conclude from our study is that rebamipide may improve outcomes of H. pylori-associated gastritis, as previously published [28][29][30][31]. And more long-term, well-designed controlled trials need to be carried out in the future to confirm the drug's relationship with H. pylori status [32].…”

Section: Discussionsupporting

confidence: 70%

Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Zhan

et al. 2008

Dig Dis Sci

View full text Add to dashboard Cite

The aim of the study was to investigate the effects of rebamipide on symptom, histology, endogenous prostaglandin, and mucosal oxygen free radicals in chronic erosive gastritis (CEG) patients by using sucralfate as a control. The trial also examined whether Helicobacter pylori infection would affect rebamipide-induced protection. A total of 453 endoscopy-confirmed CEG patients from 11 hospitals in China were enrolled in the study. They randomly received either rebamipide (100 mg t.i.d) or sucralfate (1.0 t.i.d) for 8 weeks with a ratio of 3:1. Per-protocol analysis (n = 415) showed the accumulated symptom score in the rebamipide group dropped from 5.54 +/- 0.97 to 0.80 +/- 0.47 after 8 weeks (P < 0.001 versus control). The endoscopic inflammation score in rebamipide group also decreased from 2.65 +/- 0.09 to 0.60 +/- 0.10, which showed better effects than sucralfate. It was shown a significant improvement (P < 0.01) in prostaglandin E2 (PGE(2)) contents in rebamipide-treated subjects mucosa (225.4 +/- 18.3 pg/g versus 266.7 +/- 14.7 pg/g) compared with that in sucralfate group after 8 weeks of treatment. Malondialdehyde (MDA) contents were significantly depressed both in the trial and control group. When Helicobacter pylori infection was considered, no statistically difference was found in the effect of rebamipide on either symptom or inflammation scores. In conclusion, Rebamipide demonstrated a stronger suppressive effect on the mucosal inflammation in chronic erosive gastritis than sucralfate. The gastroprotection induced by rebamipide is not influenced by H. pylori infection, which indicates its usage in the treatment of H. pylori-associated CEG.

show abstract

Section: Discussionsupporting

confidence: 70%

Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Zhan

et al. 2008

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the impact of H 2 -receptor antagonists on the accuracy of 13 C-urea breath test is controversial. Some authors have reported that ranitidine produces the occurrence of false-negative results (71,78,79), whereas others did not show any negative effect on the breath test (73,(80)(81)(82)(83). In any case, studies evaluating both PPIs and H 2 -antagonists in the same population have shown that the false-negative breath test rate caused by H 2 -blockers is far lower than that caused by the administration of a PPI (78).…”

Section: Effect Of Recent Use Of Proton Pump Inhibitors On the Accuramentioning

confidence: 99%

Accuracy of Helicobacter pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis

2006

View full text Add to dashboard Cite

Biopsy-based methods, such as rapid urease test, histology, and culture, have a low sensitivity, but a high specificity, in patients with UGIB. The accuracy of 13C-urea breath test remains very high in these patients. Stool antigen test is less accurate in UGIB. Although serology seems not to be influenced by UGIB, it cannot be recommended as the first diagnostic test for H. pylori infection in this setting.

show abstract

“…This simply reduces the concentration of the gastric bacteria and consequently lowers the delta over baseline (DOB) values. However, PPIs by themselves may also induce false-negative results during diagnostic UBT by an alternative, pH-dependent mechanism [12,13,14]. …”

Section: Introductionmentioning

confidence: 99%

Eradication of Helicobacter pylori Can Be Accurately Confirmed 14 Days after Termination of Triple Therapy Using a High-Dose Citric Acid-Based 13C Urea Breath Test

Shirin¹,

Levine

Shevah³

et al. 2005

Digestion

View full text Add to dashboard Cite

Background: Confirmation of Helicobacter pylori eradication by urea breath test (UBT) is currently performed 4–6 weeks after completion of therapy because of unacceptable false-negative results in UBTs performed earlier. Use of a high-dose citric acid test meal appears to enable accurate detection of H. pylori even during short term therapy with proton pump inhibitors. Aim: To evaluate if use of a high dose citric acid (4.0 g) test meal can decrease the interval required for confirmation of eradication after triple therapy. Methods: 233 patients positive for H. pylori were randomized to undergo UBT at 7 days or 14 days after triple therapy, and again at 6 weeks. The latter test was considered the gold standard test. Results: The UBT performed 6 weeks after the end of treatment found that 79.9% were cured. The same test 7 days after therapy found false-negative detection of H. pylori in 7.3% patients compared to 3.2% patients examined after 14 days. The sensitivity, specificity, positive and negative predictive values and accuracy for evaluation on day 14 were 80, 100, 100, 96.3 and 96.7%, respectively. Conclusions: High-dose citric acid-based UBT is a valid test for the assessment of H. pylori status 14 days after triple therapy. This may obviate the delay in instituting second-line eradication therapy, or further evaluation of the symptomatic patient unresponsive to therapy despite eradication.

show abstract

Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection

Abstract: Patients showing negative UBT results during the administration of proton pump inhibitors and H2RA should be re-examined after the cessation of these drugs to confirm the true negativity of H. pylori infection.

Cited by 29 publications

References 27 publications

Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Accuracy of Helicobacter pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis

Eradication of Helicobacter pylori Can Be Accurately Confirmed 14 Days after Termination of Triple Therapy Using a High-Dose Citric Acid-Based 13C Urea Breath Test

Contact Info

Product

Resources

About